Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCommunity-Care Uplizna Prior Auth Coverage | OpenP…
    Ask Trek AI about this page
    CurrentCommunity-CarePolicy N/A

    Uplizna (inebilizumab) Medical Benefit Medication Utilization Policy

    Customize your policy alerts

    Sign up for all Community-Care policy alerts

    Know when Community-Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity criteria, quantity limits, authorization periods, and coding for inebilizumab (Uplizna) when administered as a medical benefit for specific indications; applies to providers seeking prior authorization from the payer for patients in North Carolina.

    Policy Summary
    PayerCommunity-Care
    PolicyUplizna (inebilizumab) Medical Benefit Medication Utilization Policy
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Last ReviewMay 1, 2025
    Next Review DateMay 1, 2025
    Key ActionObtain prior authorization with documentation of diagnosis, specialist involvement, and relevant laboratory or treatment history.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2covered indications listed
    6 vialsmax loading dose
    3 vialsmax maintenance dose

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    1 yrauthorization period
    J1823HCPCS code

    Coverage criteria for inebilizumab (Uplizna)

    Initial Therapy — Covered when ALL of the following are met for each indication

    Covered when ALL of the following are met for each indication

    NMOSD Initial Therapy: 1) Diagnosis of neuromyelitis optica spectrum disorder; 2) Prescribed by, or in consultation with, a neurologist or neuro‑ophthalmologist; 3) Documentation of a positive test for anti‑aquaporin‑4 antibodies; 4) Will not be used in combination with another biologic product used for neuromyelitis optica spectrum disorder
    IgG4-related disease Initial Therapy: 1) Prescribed by, or in consultation with, a rheumatologist or provider specializing in treatment of immunoglobulin G4‑related disease; 2) Diagnosis of immunoglobulin G4‑related disease; 3) Trial of a corticosteroid was ineffective, contraindicated, or not tolerated

    Continuation Therapy — Continued coverage requires ALL of the following per indication

    Continued coverage requires ALL of the following per indication

    NMOSD Continuation Therapy: 1) Diagnosis of neuromyelitis optica spectrum disorder; 2) Will not be used in combination with another biologic product used for neuromyelitis optica spectrum disorder; 3) Patient has experienced a positive clinical response to inebilizumab (Uplizna)
    IgG4-related disease Continuation Therapy: 1) Diagnosis of immunoglobulin G4‑related disease; 2) Has experienced a positive clinical response to inebilizumab (Uplizna)

    Quantity Limits — Coverage is subject to the following quantity limits

    Coverage is subject to the following quantity limits

    Loading Dose Limit: If approved, inebilizumab may be authorized for quantities of up to 6 vials/180 days (1 vial = 10 mL)6 vials/180 days
    Maintenance Dose Limit: If approved, inebilizumab may be authorized for quantities of up to 3 vials/180 days (1 vial = 10 mL)3 vials/180 days

    Use of inebilizumab (Uplizna) in combination with another biologic product indicated for neuromyelitis optica spectrum disorder is not permitted. Requests for initial or continued therapy must document that the drug will be used as monotherapy for NMOSD and will not be administered together with any other NMOSD-targeted biologic agent.

    Billing and coding

    Applicable HCPCS CodesHCPCSCovered
    J1823Injection, inebilizumab-cdon, 1 mg
    vial size
    Vial size1 vial = 10 mL
    Unit descriptionEach vial contains 10 mL of inebilizumab
    Use in quantity limitsQuantity limits and dose calculations reference vials (e.g., 6 vials/180 days loading)

    Requirements and actions for providers

    Prior Authorization

    Prior authorization required with supporting documentation

    Prior authorization is required for inebilizumab (J1823) and must be submitted with documentation that supports the requested diagnosis, involvement of an appropriate specialist, and relevant laboratory or treatment history per the indication-specific criteria.

    • Applicable code: J1823
    Step Therapy

    No further step therapy beyond corticosteroid requirement for IgG4-related disease

    There is no additional step therapy sequence specified in this policy beyond the requirement for a trial of corticosteroids (or documentation of corticosteroid intolerance/contraindication) for IgG4-related disease.

    • For IgG4-related disease, a trial of a corticosteroid that was ineffective, contraindicated, or not tolerated must be documented.

    Background

    Inebilizumab (Uplizna) is a monoclonal B‑cell depleting biologic indicated for treatment of neuromyelitis optica spectrum disorder associated with anti‑aquaporin‑4 antibodies. Use for NMOSD should be coordinated with a neurologist or neuro‑ophthalmologist and requires documentation of a positive anti‑AQP4 antibody test. The agent is also considered for immunoglobulin G4‑related disease when prescribed by or in consultation with an appropriate specialist and after a trial of corticosteroids has been ineffective, contraindicated, or not tolerated.

    Key definitions

    NMOSD (AQP4-positive)
    TermNMOSD (AQP4-positive)
    DefinitionNeuromyelitis optica spectrum disorder with positive anti‑aquaporin‑4 antibodies (AQP4‑IgG)
    Specialist involvementPrescribed by, or in consultation with, a neurologist or neuro‑ophthalmologist
    IgG4-related disease
    TermIgG4-related disease
    DefinitionImmunoglobulin G4-related disease requiring specialist management and prior corticosteroid trial failure, contraindication, or intolerance
    Specialist involvement

    Initial therapy criteria (detailed by indication)

    Initial Therapy — Initial therapy criteria per indication

    Initial therapy criteria per indication

    NMOSD Initial: Diagnosis of NMOSD; prescribed by or in consultation with neurologist or neuro‑ophthalmologist; positive anti‑AQP4 antibody test; not used with another NMOSD biologic
    IgG4 Initial: Diagnosis of IgG4‑related disease; prescribed by or in consultation with a rheumatologist or provider specializing in treatment of IgG4‑related disease; trial of corticosteroid was ineffective, contraindicated, or not tolerated

    Continuation therapy criteria (detailed by indication)

    Continuation Therapy — Continuation coverage requirements per indication

    Continuation coverage requirements per indication

    NMOSD Continuation: Diagnosis of NMOSD; no combination with another NMOSD biologic; documented positive clinical response to inebilizumab
    IgG4 Continuation: Diagnosis of IgG4‑related disease; documented positive clinical response to inebilizumab

    Step therapy requirements

    StepRequirement
    1No other step therapy requirements specified beyond the requirement that, for IgG4‑related disease, a trial of corticosteroids was ineffective, contraindicated, or not tolerated.
    2For IgG4‑related disease, documentation of corticosteroid trial failure, intolerance, or contraindication is required prior to approval; no additional medication step sequence is specified.

    Quantity limits and dosing caps

    inebilizumab (Uplizna) quantity limits
    Loading dose limitUp to 6 vials per 180 days
    Maintenance dose limitUp to 3 vials per 180 days
    Reference vial sizeLimits expressed in vials; 1 vial = 10 mL

    Site of care considerations

    Note

    No site‑of‑care restriction specified

    The policy does not impose site‑of‑care restrictions; infusion may be administered in an infusion center per usual practice.

    Policy Summary
    PayerCommunity-Care
    PolicyUplizna (inebilizumab) Medical Benefit Medication Utilization Policy
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Last ReviewMay 1, 2025
    Next Review DateMay 1, 2025
    Key ActionObtain prior authorization with documentation of diagnosis, specialist involvement, and relevant laboratory or treatment history.
    SourceLink
    On This Page
    Coverage criteria for inebilizumab (Uplizna)Billing and codingRequirements and actions for providersBackgroundKey definitionsInitial therapy criteria (detailed by indication)Continuation therapy criteria (detailed by indication)Step therapy requirementsQuantity limits and dosing capsSite of care considerations
    Documentation Required

    Required documentation to support authorization

    Documentation submitted with the authorization request must include the patient’s diagnosis and evidence of specialist involvement, and for NMOSD must include a positive anti‑aquaporin‑4 antibody test; for IgG4‑related disease include documentation of a corticosteroid trial that was ineffective, contraindicated, or not tolerated.

    • NMOSD: positive anti‑AQP4 antibody test; prescribed by or in consultation with a neurologist or neuro‑ophthalmologist
    • IgG4-related disease: prescribed by or in consultation with a rheumatologist or specialist; documentation of corticosteroid trial failure, contraindication, or intolerance
    Denial Risk

    Triggers for denial

    Requests may be denied if they do not include the required diagnosis, lack prescriber specialty or documented consultation, do not provide a positive AQP4 antibody test when seeking treatment for NMOSD, or fail to document a corticosteroid trial failure/contraindication/intolerance for IgG4‑related disease.

    • Missing diagnosis of NMOSD or IgG4‑related disease
    • No documentation that prescription was by, or in consultation with, the appropriate specialist
    • No positive anti‑aquaporin‑4 antibody test when indicated for NMOSD
    • For IgG4-related disease, no documentation of corticosteroid trial failure, contraindication, or intolerance
    Prescribed by, or in consultation with, a rheumatologist or provider specializing in IgG4-related disease